>future cometh short term>>>>multi-bagger BISU_DD>>>>>>>>>>>>>$$Dr. Chandrasekhar Mallangi -- Former Nestle Beverage Innovator and Product Lines Developer -- Named Chief Scientist at Bio-Solutions Corp 2012-06-05 19:04 ET
Nestle in $11.85_billion_deal to acquire Pfizer's infant-nutrition business Monday, Apr 23, 2012 05:15 am | John Heilprin, The Associate Press Share Print
((will be interesting a little update with Gallaher...vs nestlé... @0.30-0.40 easily in-short_term_
http://www.bio-solutionscorp.com/August_29__2011.pdf Between 2004 & 2008, Mr. Gallagher was Chairman and CEO of Sweet Success Corporation. Bill directed the funding and expansion of the Sweet Success Brand. Sweet Success is a supplement/meal replacement drink acquired from Nestle. Sweet Success developed a new line which included seven new beverages. Sweet Success products were later licensed to an Asian company in 2009.
Trader...just for fun....BISU + Gallagher...+ Nestlé..Hmmm!! future agreement perhaps..... In this Feb. 22, 2007 file photo two journalists talk behind a Nestle logo after a press conference of the food and drinks giant Nestle, in Vevey, Switzerland. THE CANADIAN PRESS/AP, Keystone, Laurent GillieronGENEVA - Swiss food and drink giant Nestle SA announced a deal Monday to acquire Pfizer Inc.'s infant-nutrition business for $11.85 billion in a bid to boost sales in emerging markets.
The company based in Vevey, Switzerland said the acquisition would "enhance its position in global infant nutrition" because 85 per cent of the Pfizer Nutrition unit's sales is in emerging markets, many of which have large, fast-growing populations.
The deal would particularly help Nestle to boost growth in China and maintain its position as one of the world's largest sellers of infant formula. It is subject to regulatory approval, however, and Nestle, since it already sells so much infant formula, may face some antitrust hurdles to complete the deal.
Nestle's shares fell 3 per cent to 55.30 Swiss francs ($60.71) after the Zurich exchange opened.
The maker of Nescafe, Haagen Dazs and Jenny Craig said it estimated that the Pfizer unit's 2012 sales would bring $2.4 billion.
"Infant nutrition has been at the heart of our company since it was founded in 1866," Nestle CEO Paul Bulcke said in a statement. "Pfizer Nutrition is an excellent strategic fit and this acquisition underlines our commitment to be the world's leading nutrition, health and wellness company."
Nestle's offer beat a rival joint bid by Groupe Danone and Mead Johnson Nutrition Co. for the infant-nutrition business, which Pfizer had put up for sale last July along with a separate animal-health business unit.
Pfizer, the world's largest drug maker, has been shedding its noncore businesses as it moves to focus on developing new prescription drugs. Last year it suffered the patent expiry of blockbuster drug Lipitor, the cholesterol fighter.
It also sold its business unit that makes drugs in capsule forms to KKR & Co. last August for $2.4 billion.
Nestle forecast Friday that 2012 will be a challenging year but reported that first-quarter sales rose a healthy 5.6 per cent from a year earlier, fueled by strong growth in emerging markets and higher retail prices.
"The takeover affirms Nestle's worldwide No. 1 position in one of the most attractive growth markets," said bank analyst Patrik Schwendimann of Zuercher Kantonalbank. "One positive side effect is that speculation about large acquisitions by Nestle will calm down for the foreseeable future."
Bio-Solutions Corp. Acquires Type 2 Defense Diabetes Supplement Beverage Montreal Canada- 9/29/2011(OTCBB:BISU) - Bio Solutions Corp. is pleased to announce the closing of the acquisition of Type2 Defense: A powder form diabetic nutritional supplement drink. Type2 Defense proprietary blend was developed by Dr. Chandrasekhar Mallangi. Dr. Mallangi was previously the head of Nestle Nutritional product development for 25 years. “We are very pleased to surround ourselves with high caliber people as Dr. Mallangi. As a fellow scientist, I can appreciate the work and dedication that has brought us to this point,” stated Gilles Chaumillon, President and CEO. “As we know, pre and type2 diabetes is one of the top five diseases in the world. T2 is composed of high antioxidant ingredients that have a proven clinical effect on keeping glucose levels in humans at normal levels. This proprietary blend of proven ingredients is the essential ingredient in the T2 Defense formula.” T2 Defense will be packaged in a 30-pack, easy to deliver powder form drink to be taken once a day. “T2 Defense is the first of its kind,” stated Gilles Chaumillon, President and CEO. “I am strictly concentrating on the build out of our company. We at Bio Solutions Corp are trying to build value for shareholders. We will be launching a massive Search Engine Operation (SEO) campaign in order to drive interest and online sales. We would like to generate as much interest as possible in the product and building an online presence (and a brand) is a key component. Based on my industry relationships and past successes, I believe once we have the public’s interest, the rest should follow. SEO will play a vital role,” stated Bill Gallagher, Executive Vice-President. “Type2 Defense was developed as a system that helps reduce and control the onslaught of diabetes. With a sound product, social marketing on the web, and top diabetes nutritionalists on board, we believe we have all the ingredients to make this product a huge success with substantial revenues by year two,” stated Bill Gallagher, Executive Vice-President. For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.bio-solutionscorp.com Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forwardlooking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law. Contact Investor & Public Relations Harald van der Kam 484-961-7052
Share structure (aprox 17% float..) Shares Outstanding 61,970,397 a/o Nov 21, 2011 Float 15,000,000 a/o May 12, 2011 Authorized Shares 90,000,000 a/o May 27, 2011
BISU-Type 2 defense is the product of many years of R&D and clinical studies. Clinical's info will be published at later date, as due diligence proceeds. “Although this is a simple LOI, in the eyes of the market, this is a major accomplishment for our company. After our hard past time, we at Bio-Solutions Corporation have striven to find the most beneficial acquisition target for our shareholders.” According to the CDC's 2011 diabetes Fact Sheet. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf there is an estimated 100 Plus Million Americans at risk of diabetes in the following order (Data from the 2011 National Diabetes Fact Sheet (released Jan. 26, 2011)) Total prevalence of diabetes 25.8 million children and adults in the United States—8.3% of the population—have diabetes. Diagnosed:18.8 million people Undiagnosed: 7.0 million people Prediabetes:79 million people* New Cases:1.9 million new cases of diabetes are diagnosed in people aged 20 years and older in 2010. * In contrast to the 2007 National Diabetes Fact Sheet, which used fasting glucose data to estimate undiagnosed diabetes and prediabetes, the 2011 National Diabetes Fact Sheet uses both fasting glucose and A1C levels to derive estimates for undiagnosed diabetes and prediabetes. These tests were chosen because they are most frequently used in clinical practice. “Given the two types of Diabetes (Type 1 and Type 2), our product will cater to obviously Types 2 patients, which are 90-95% , of all diabetics. Our supplement will aid to combat in the major against complications of Diabetes which include: 1) Heart disease and stroke 2) High blood pressure • In 2005-2008, of adults aged 20 years or older with self-reported diabetes, 67% had blood pressure greater than or equal to 140/90 mmHg or used prescription medications for hypertension. 3) Kidney disease • Diabetes is the leading cause of kidney failure, accounting for 44% of new cases in 2008. • In 2008, 48,374 people with diabetes began treatment for end-stage kidney disease in the United States. • In 2008, a total of 202,290 people with end-stage kidney disease due to diabetes were living on chronic dialysis or with a kidney transplant in the United States. 4) Nervous system disease (Neuropathy) • About 60% to 70% of people with diabetes have mild to severe forms of nervous system damage. According to Dailyfinance.com (1/27/11 Big Pharma Article) : “ In 2009, the U.S. diabetes market grew 17% from 2008, reaching $14.9 billion, according to data from health care information company IMS Health. Worldwide, the market generated sales of over $25 Billion, according to independent business information provider Vision again. By 2019, Morningstar projects the worldwide diabetes market, excluding insulin, will grow to over $55 billion... "We stand by our core value of wellness and Improving Life Through Science." stated President and CEO Gilles Chaumillon. For more information on Bio-Solutions Corp. and its products, please visit the company's website at www.bio-solutionscorp.com Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forwardlooking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.
Market Data 
Markets 
AI
